Potential buyers prepared to chase arimoclomol approval, Orphazyme deputy chair says
![Photo: Nikolaj Skydsgaard/Reuters/Ritzau Scanpix](https://photos.watchmedier.dk/watchmedier/resize:fill:3840:0:0/plain/https://photos.watchmedier.dk/Images/article13982357.ece/ALTERNATES/schema-16_9/20210618-130542-1-6061x3402ma%2520(1).jpg)
Embattled biotech firm Orphazyme announced last week that several potential buyers had made bids to buy all of the company’s assets and operations.
Read the whole article
Get access for 14 days for free. No credit card is needed, and you will not be automatically signed up for a paid subscription after the free trial.
With your free trial you get:
Get full access for you and your coworkers
Start a free company trial todayRelated articles
Orphazyme creditors approve restructuring plan
For subscribers